Hyperthermia Combined with Radiation for Locally Advanced Prostate Cancer
Hyperthermia Combined with Radiation for Locally Advanced Prostate Cancer
Radiation therapy is a common treatment for locally advanced prostate cancer, but researchers have explored whether adding hyperthermia may enhance its effectiveness. Hurwitz and colleagues reported the long-term outcomes of a clinical study from the Dana-Farber Cancer Institute evaluating the combination of regional hyperthermia and radiation therapy in patients with locally advanced prostate cancer.
In this clinical study, patients with locally advanced prostate cancer received external beam radiation therapy along with regional hyperthermia treatments. Hyperthermia was delivered using specialized equipment designed to raise the temperature of tumor tissues, with the goal of increasing tumor sensitivity to radiation. Patients were followed long term to assess treatment response, disease control, and survival outcomes.
The results showed encouraging long-term outcomes, with many patients achieving durable local disease control following the combined treatment approach. The authors noted that hyperthermia may enhance the effectiveness of radiation by improving tumor oxygenation and increasing the susceptibility of cancer cells to radiation-induced damage.
While additional research is needed to further define the role of hyperthermia in prostate cancer treatment, this study provides long-term clinical evidence supporting the potential benefit of combining thermal therapy with radiation. These findings contribute to a growing body of literature suggesting that hyperthermia may help improve treatment outcomes when used alongside conventional cancer therapies.
Reference:
Hurwitz MD, Hansen JL, Prokopios-Davos S, Manola J, Wang Q, Bornstein BA, Hynynen K, Kaplan ID. Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94-153. Cancer. 2011;117(3):510–516. doi:10.1002/cncr.25619. PMID: 20886629.
